{"name":"Atea Pharmaceuticals, Inc.","slug":"atea-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AT-527 Formulation 1","genericName":"AT-527 Formulation 1","slug":"at-527-formulation-1","indication":"Other","status":"phase_1"},{"name":"AT-527 Formulation 2","genericName":"AT-527 Formulation 2","slug":"at-527-formulation-2","indication":"Other","status":"phase_1"},{"name":"AT-527 fasted","genericName":"AT-527 fasted","slug":"at-527-fasted","indication":"Other","status":"phase_1"},{"name":"AT-527 fed","genericName":"AT-527 fed","slug":"at-527-fed","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"AT-527 and Probenecid","genericName":"AT-527 and Probenecid","slug":"at-527-and-probenecid","indication":"COVID-19","status":"phase_1"},{"name":"AT-527 single dose","genericName":"AT-527 single dose","slug":"at-527-single-dose","indication":"Treatment of SARS-CoV-2 infection","status":"phase_1"},{"name":"Bemnifosbuvir (BEM)","genericName":"Bemnifosbuvir (BEM)","slug":"bemnifosbuvir-bem","indication":"COVID-19 (SARS-CoV-2 infection)","status":"phase_3"},{"name":"Bemnifosbuvir-Ruzasvir","genericName":"Bemnifosbuvir-Ruzasvir","slug":"bemnifosbuvir-ruzasvir","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1-6","status":"phase_3"}]}],"pipeline":[{"name":"AT-527 Formulation 1","genericName":"AT-527 Formulation 1","slug":"at-527-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 Formulation 2","genericName":"AT-527 Formulation 2","slug":"at-527-formulation-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 and Probenecid","genericName":"AT-527 and Probenecid","slug":"at-527-and-probenecid","phase":"phase_1","mechanism":"AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.","indications":["COVID-19"],"catalyst":""},{"name":"AT-527 fasted","genericName":"AT-527 fasted","slug":"at-527-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 fed","genericName":"AT-527 fed","slug":"at-527-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-527 single dose","genericName":"AT-527 single dose","slug":"at-527-single-dose","phase":"phase_1","mechanism":"AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.","indications":["Treatment of SARS-CoV-2 infection"],"catalyst":""},{"name":"Bemnifosbuvir (BEM)","genericName":"Bemnifosbuvir (BEM)","slug":"bemnifosbuvir-bem","phase":"phase_3","mechanism":"Bemnifosbuvir is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.","indications":["COVID-19 (SARS-CoV-2 infection)","Respiratory viral infections"],"catalyst":""},{"name":"Bemnifosbuvir-Ruzasvir","genericName":"Bemnifosbuvir-Ruzasvir","slug":"bemnifosbuvir-ruzasvir","phase":"phase_3","mechanism":"Bemnifosbuvir is a nucleoside analog that inhibits hepatitis C virus (HCV) RNA-dependent RNA polymerase, while ruzasvir is an NS5A inhibitor that blocks viral protein function and replication.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1-6"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE9mVzZTTFFIemhFem04QWZDQ2NMWGhTLThkSFZaRXlvN0N1SmNqU1FFZHlMdnEwcHdpMnp6LXVHSjEwdXZtR2MzSndzZw?oc=5","date":"2026-04-02","type":"pipeline","source":"Benzinga","summary":"Eton Pharmaceuticals Inc (ETON) Stock Price, Quote, News & History - Benzinga","headline":"Eton Pharmaceuticals Inc (ETON) Stock Price, Quote, News & History","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5VT0tINjBIM1hMVkE4MmxHbHc5d0JhcUd0eUlmV3VrQ3k3Q1A4ckNESzNlUnZvVmwyVzV3MDg3TzF5MkZEYkdxTjZGRzhJbmxleEdka01MOGdEanhKb1NueWs0WWRUcmc1NDd0VHNB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR) - Stock Titan","headline":"If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaGR3bnlEN09LUkpUcF9VYWZZeWUxdlc3WjlsWW5CMnFtZ3VkWjhmRXkxNmZhV2Z1SGpENC1nTEs3eEFaaDhzRjZhb1B4OFlZMmVhcnduMF84N1Z6UjJCNnU5LTFIbzBocVFCaUxxbkloaXV5cWF4NFhWQ3BQVUlHaE9DU18zT2lQMEhTUUFtcDJralF6VzJoRWVqMHFza2hmeGJqWWNGVE1kazFwazhWNnJhV3I2eXliZk5fYXZMQ3dWSGs?oc=5","date":"2026-03-05","type":"earnings","source":"The Globe and Mail","summary":"Atea Pharma (AVIR) Earnings Call Transcript - The Globe and Mail","headline":"Atea Pharma (AVIR) Earnings Call Transcript","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPdFVMN2xKOHliRDBjUFBBWUpDRXFWVXg1aEYwV1EzbjlVQl9HTUc4QV8yY24tWExBcnRYVURfNExzeEhoUHZOQTJSVWVKNExhYjFHVlVzbDV3b3VpTVFkelUtMnRnVmt6RHBXLUZITXJVU0xiN1poSkJwMUhsb3ZxYm15SHJ2UW9yQk9lWk43RDZESnJvTXVjNHFwVkkwVzA1aXh1WlRXbGs2ajZFX3hYNTU3WUw4UmduZDh2RFA1QTVSb0JtV0Z0eGladzN3UzByX1llMDN5NjlyUQ?oc=5","date":"2026-01-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology","headline":"JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTEVJZVB3UjlXYmxtdXhZWFpTOXJHWXpGRHNObkdjUl9nRUxVVUxTU21ZWHNLU0dvTGtNVjdLbkc0ZHZ2WUYtNjQ4c29iNjI5Q1V1LUY5cTY0dEI2SzdJOUtKM2tLd25iZS0ycC1JSnBDdE1pN3lJRnhuS1hEOWhnMzI5TFU4VU15UzNXNDFTdnBLUnIwMGpOYUxscW4zSFRTbmNkeF9BSVNuLU1VUTV3ODVvem5mOW8xQ3hfRkluNzdfdw?oc=5","date":"2025-12-23","type":"trial","source":"Seeking Alpha","summary":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha","headline":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPYWpwRWxDZ1dQUklpTC1BbzVjcW1ZNXlvY2hkLW02VHVIWmhvWDEwZF8tUTlJak1PbkRMVTVXaTF6QXRWT1NTcUZ5QnYtdUhHcTUzV0t0UHZMZ2JveGQ1Y0I4UDFvZEUtUDZoZDdXZDR5YWlOZzkwUWpOZzNmNnZxRDUzclY5TlppUmEyMTV0UDM3Y0FWWS1yQm1VYmJrTXAtZ1dfUWcwVQ?oc=5","date":"2025-12-23","type":"pipeline","source":"RTTNews","summary":"Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews","headline":"Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-19","type":"deal","source":"simplywall.st","summary":"Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock - simplywall.st","headline":"Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxObUEzWEliN2FGS1VhcEF4Uy1PcERveWljd2ZxM1ZaWVZicEZiVmw4MzVEaEo1MmJXdktCVTJpVnRDVy03aU9ITEpBVnJSQ0hxR25DMEplSGpwV1BoQ1I1SFlYcmxETkNqQW1odGVubGFIc1ZMMFIxblZVenBtcTZlMXpxdXpmZWJJYjJwZkFJU2VSektlejlQVzJMVWkxOFNsU1NSYVhwcjd1bzZz?oc=5","date":"2025-08-12","type":"pipeline","source":"BioSpace","summary":"U.S. Antiviral Drugs Market Size to Surpass USD 21.94 Billion By 2034 - BioSpace","headline":"U.S. Antiviral Drugs Market Size to Surpass USD 21.94 Billion By 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbG1wTHpWc25WQXZuM2taOGJzV2NXU1UwS3lTdC16WG5UVWQxb1JzeDEwMFNsTFVBRnBaY081MUlBZGY4aHM5WW5haEo5NDI1ZDRfOGZBZy1CUW5La2xzZVEybVJPV040b1l0RDlhdXM3azRGZ1d2NkNhNGRQLUg0UTN3aGNQZFVib2VsdlU3ZGFLbXBMbkdzRW1jenA1NnpqamxDYjQ3TGI3QQ?oc=5","date":"2025-03-07","type":"trial","source":"Fierce Biotech","summary":"Atea offloads a quarter of its workforce, gears up for phase 3 HCV trials - Fierce Biotech","headline":"Atea offloads a quarter of its workforce, gears up for phase 3 HCV trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxONE11azBBZjQ2NnlyQjNOMjNWQVVUcjIwOXNVYTRCT2ZJcWx6bzVoZEhTV0FvV1B6QTBjUUEyd0czcHUzeVItSW9ackRGS2t4V3RhWEYyZVpLTVFaOGU4MG5zUktHd1BZQlp6VGowU3lhOUNiZ0Jyc0puYVcxSndKQkxkWmk?oc=5","date":"2023-05-23","type":"deal","source":"BioPharma Dive","summary":"Concentra bids on Atea, seeking to acquire another struggling biotech - BioPharma Dive","headline":"Concentra bids on Atea, seeking to acquire another struggling biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQb2lMNEE2MUNRMjd2NmI1b3AyRC1QaTVuRjB0dk9WRXFiV0JHVUhmaUh3VHJMblRtRThjbVh4b1JCTTExa04yRVl4S1dfOGNDUEVKT19obG5LWU5sUTNGcDdCbWN3TmFuQWhfdWFFMG5vei0wZjR2cHlRU3dHblZJQ2pUR0c2LVJ3VW04RmY5X2RqTFlkZXc?oc=5","date":"2021-11-04","type":"pipeline","source":"The Motley Fool","summary":"Is There Any Hope for Atea Pharmaceuticals Stock? - The Motley Fool","headline":"Is There Any Hope for Atea Pharmaceuticals Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQTVNuLUpWMkRqaGI2UGd2YVE1Y0hwdFE1N3dtaGY2dGZKVFBwTEZEb21MTGc4T3JvX3JxbEdhY3Q4Zm4zQmxhQVB4ZnpXS2xWTGpkUWJMamNJWmNrTWlkbVhKeC1qWUI1alROSzB2SE1ESDJ4djZuRGMyM0I5RVlRdzdIVnhxWEtIQnlna05DSHRENENqZG5ZQk41MGtIcDg0QldrX1pyTDVtb1ZRWmlNTGtLRkFGN3M?oc=5","date":"2020-05-20","type":"pipeline","source":"baincapital.com","summary":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing - baincapital.com","headline":"Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_1":6,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}